T1	intervention 0 9	Tamoxifen
T2	location 67 74	Italian
T3	duration 528 565	October 1, 1992, to December 31, 1997
T4	No-of-participants 567 571	5408
T5	eligibility 582 626	healthy women who had undergone hysterectomy
T6	control 705 712	placebo
T7	duration 717 724	5 years
T8	outcome 942 955	breast cancer
T9	control-value 906 908	74
T10	intervention-value 918 920	62
T14	outcome 1064 1086	rates of breast cancer
T17	outcome 1493 1504	hot flashes
T18	outcome 1541 1558	vaginal discharge
T19	outcome 1599 1619	urinary disturbances
T20	outcome 1665 1674	headaches
T21	outcome 1743 1763	Hypertriglyceridemia
T22	outcome 1800 1821	thromboembolic events
T23	outcome 1862 1903	cardiac arrhythmia or atrial fibrillation
T15	control-value 1321 1325	6.26
T24	control-participants 1330 1334	1000
T11	intervention-value 1359 1363	1.50
T12	intervention-participants 1368 1372	1000
